ArticleWorld journal of surgical oncology2025
SPOCD1 expression in clear cell renal cell carcinoma: its implications for the prognosis and immunotherapy.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRecent advancements in the study of SPOCD1 have highlighted its potential role in carcinogenesis. Nevertheless, the specific correlation between SPOCD1 expression level, survival outcomes, and immune cell infiltration in clear cell renal cell carcinoma (ccRCC) has not been fully elucidated.
methodsTo determine the possible connection between SPOCD1 expression levels, clinical pathological information, and overall survival (OS) in individuals with ccRCC, multiple databases encompassing TCGA, Gene Expression Profiling Interaction Analysis (GEPIA), and UALCAN were employed. Additionally, a comprehensive examination of the connection between tumor-infiltrating immune cells (TIIC) and SPOCD1 was executed through TIMER, GEPIA, and TISIDB databases. Western blot (WB) and Quantitative Real-Time PCR (qRT-PCR) were implemented to measure the SPOCD1 expression level in ccRCC cell lines. Immunohistochemistry (IHC) staning was utilized to identify the SPOCD1 expression in ccRCC tissues.
resultsSPOCD1 expression was discovered to have a notable correlation with the TNM stage, pathologic stage, and histologic grade. Elevated SPOCD1 expression exhibited associations with poor Disease-Specific Survival (DSS) and OS outcomes (p < 0.01). Subsequent evaluation identified a notable connection between SPOCD1 overexpression and the expression of immunomodulators and chemokines. Additionally, SPOCD1 overexpression was linked to increased infiltration of macrophages, regulatory T cells (Treg), Th1 cells, dendritic cells (DC), and Th2 cells in ccRCC tissues. Validation through qRT-PCR, WB, and IHC confirmed that SPOCD1 acts as an oncogene in ccRCC.
conclusionsSPOCD1 represents a potential prognostic indicator for patients with ccRCC. Elevated SPOCD1 expression is strongly associated with unfavorable clinicopathological features, poorer survival outcomes, and increased immune cell infiltration in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.